Search

everythinglearnresearchcommunity

for

Search:↓

The 2012 SLICC criteria provide an updated method for classifying Systemic Lupus Erythematosus.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Routine eye exams may be needed for alopecia areata patients due to common eye issues.

Certain hair and scalp features can predict the severity of alopecia areata.

Disease-specific tools better assess quality of life in alopecia areata patients.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

Alopecia areata severity and symptoms vary by race and ethnicity.

Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.

The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.

A comprehensive scoring system for alopecia areata severity is needed.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

More lesions mean more severe alopecia areata.

Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.

A new AIRE gene mutation causes rare autoimmune symptoms in a Lebanese boy.

People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.

The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

Diagnosing hair loss disorders needs clinical, dermoscopic, and histological differences, and checking menstrual cycle, weight changes, drug therapy, and nail changes.

Alopecia areata greatly affects the quality of life for children and their families.

Certain hair and scalp features indicate a worse outcome in alopecia areata.

New criteria for diagnosing frontal fibrosing alopecia include specific scalp and eyebrow hair loss as major factors and other hair loss areas and hair analysis as minor factors.

Alopecia Areata patients experience higher social appearance anxiety due to visible hair loss.